hERG channel plays an important role in cardiac safety assessment. Mediford performs Best Practice hERG assay in compliance with GLP (Good Laboratory Practice) according to the new ICH S7B Guideline Q&As. Our staff’s proficiency with the patch-clamp method provides our clients with high-quality data quickly and efficiently.

Mediford Corporation has introduced microsampling for non-clinical toxicity studies taking into consideration the 3Rs of animal testing. Microsampling is a technique in which a small amount of blood is collected to measure drug concentrations. By using this technique, fewer animals are used than with conventional methods, and the amount of test substance required can be reduced, which is expected to result in total costs being lower.

Mediford Corporation offers a variety of contract services from establishment and banking of PDX-derived cell lines to conducting pharmacological studies at the GLP-certified facilities of Kumamoto Laboratories. The PDX models are more predictive of clinical outcomes than conventional "cancer cell lines" and will be useful for your research and development purposes.

Mediford Corporation provides various contract services using clinical isolates (PDC: Patient-Derived Cell) established at the National Cancer Center in Japan.

We provide a wide range of services in the development of regenerative medicine products from consulting to medical writing for diseases that are difficult to treat with conventional methods. We support each stage of the development process up to submission of application for approval by providing contract services that meet a wide variety of research needs, including toxicity studies (GLP), efficacy and biodistribution studies (reliability standards), and medical writing at research facilities fully accredited by AAALAC.

Mass spectrometry imaging (MSI), is a molecular imaging technique that visualizes the distribution of compounds present on tissue sections by ionizing and measuring them with a mass spectrometer. Mediford Corporation conducts various analyses using cutting-edge MSI equipment.

For many years, we have been entrusted with PBMC isolations in clinical trials. We pick up blood samples from study sites, and highly skilled researchers conduct the PBMC isolation process at our GLP laboratory located in Itabashi, Tokyo.

Mediford Corporation conducts the development and validation of analytical methods, as well as the determination of drug concentrations for nucleic acid drugs in biological samples such as plasma and tissue under the framework of GLP (Good Laboratory Practice). We also carry out metabolite screening studies for nucleic acid drugs in accordance with reliability standards.

In recent years, drug development has expanded beyond small molecule drugs to include a range of molecule sizes ―from medium-sized to large molecules― such as nucleic acid drugs, antibody drugs and gene therapy products, utilizing a variety of drug discovery technologies.
Mediford Corporation leverages decades of expertise in small molecule drugs, combined with cutting-edge equipment, to provide reliable data across various modalities.